Verdane Partners with Climate Tech Leader Cleanwatts
Verdane, the European specialist growth equity investor, through its impact fund Idun, has invested in Cleanwatts, an energy software company on a mission to accelerate global energy decarbonization and alleviate energy poverty. Cleanwatts, which grew year-on-year revenues by 65% in 2021 and expects 2022 revenue growth of more than 200%, offers innovative energy management solutions that help local communities unlock the benefits of optimized renewable energy consumption, generation, storage, trading, and balancing. The partnership, in which Verdane is set to invest up to EUR25m, will draw on Verdane’s deep expertise of scaling SaaS companies, international network and in-house team of operating specialists.
Cleanwatts is a Portuguese energy management software company that deploys renewable energy communities (RECs) in countries with advanced legal frameworks and policies that enable the activation of local energy markets. The company operates in Portugal (HQ), Italy, Spain, and the United States, with plans to expand further into Europe and Asia. REC members can include residents, commercial and industrial businesses, municipal buildings, schools, hospitals, and universities that collectively contribute to the clean energy transition while advancing energy efficiency, lowering electricity bills, and creating jobs within the local economy. By supporting citizen and commercial participation IoT enabled energy load management, energy communities can also help provide flexibility and local grid resiliency through demand-response and storage.
Cleanwatts is in the process of building more than 80 energy communities, several of which are already operational. Currently, the company manages and controls two terawatt hours of energy – the equivalent of over 500,0001 households’ annual consumption – and runs over 15MW in aggregated rooftop solar PV capacity through Cleanwatts™ OS, its modular operating system designed to manage energy communities. Cleanwatts REC members can lower their average energy costs by up to 60%.
In keeping with the company’s goal of removing friction and complexity from the launch of RECs, Cleanwatts complements its digital offering with zero upfront investment requirements for the adoption of distributed energy resources, including PV solar capacity, energy storage systems, EV charging infrastructure and electrification of heating and cooling.
Cleanwatts plans to allocate Verdane’s investment primarily to accelerate and expand its commercial presence in target markets, and to further develop Cleanwatts™ OS to anticipate evolving needs in local energy markets. Together with Verdane, the company will also assess M&A possibilities if and where accretive to the Cleanwatts value proposition. To meet growing market demand for its services, the company expects to grow headcount by 50% over next 6-12 months, adding 40+ resources to its current team of 70 in Europe and the US.
Verdane’s investment coupled with Cleanwatts’ unique and innovative capabilities, will enable Cleanwatts to tackle the world’s energy poverty problem, which is defined as the “lack of access to sustainable modern energy services and products,” by the WEF. Energy poverty affected between 50 and 125 million people across Europe in 20202 - a figure that has increased dramatically due to Russia’s invasion of Ukraine and record-high inflation.
Michael Pinto, CEO and Co-Founder of Cleanwatts, commented: “Mitigating the rising cost of energy and supply constraints, while responding to an increasing demand for electricity and meeting decarbonization targets is an enormous global challenge. Fortunately, digitally enabled RECs now represent both an effective and efficient solution to address these problems. A wide range of viable technologies and regulatory frameworks are finally in place for our society to reframe its relationship with energy and pave the way for a cleaner, fairer, and more sustainable future. We are proud to partner with Verdane to address the rapid paradigm shift towards a more efficient and resilient decentralized energy network.”
Bjarne Kveim Lie, Co-Founder & Managing Partner at Verdane, said: “Our team is impressed by Cleanwatts’ potential to provide a global solution to a local problem that is causing tens of millions of households in the US and the UK to forego food and medicine to pay energy bills or to go without electricity at all for parts of the year. We look forward to deploying our extensive experience scaling SaaS businesses and harnessing our in-house team of operating experts to power Cleanwatts through this critical scaling phase of its growth journey.”
Verdane Idun is classified as “Article 9” under the European Union’s Finance Disclosure Regulation and closed in January 2022 at its hard cap of € 300 million, over its target fund size of € 225 million. Idun makes investments focused on driving impact in three clusters: energy transition; sustainable consumption; and resilient communities. Previous investments include Auntie, a digital provider of workplace wellbeing services; in Spond, a digital enabler of grassroot sports and physical health; and EVA Global, a managed services provider supporting the global shift to electric vehicles. To date, Verdane has invested in over 30 sustainable society businesses.
Cleanwatts is a clean tech company resolutely focused on simplifying, amplifying, and accelerating the energy transition for local communities around the world. We generate value through Cleanwatts™ OS, our modular, highly interoperable, and localizable platform designed to address energy related needs in local energy market settings. We operate behind the meter and in front of the meter, seamlessly connecting the dots between energy generation, storage, consumption, trading and balancing at every level of an energy community. We also combine our digital offering with zero upfront investment solutions to remove friction from the incorporation of distributed energy resources that drive the energy transition, including PV solar capacity, energy storage systems, EV charging infrastructure and electrification of heating and cooling for the built environment. We are building a world in which clean energy is decentralized, digitalized, and democratized.
More info: www.cleanwatts.energy
Follow Cleanwatts on LinkedIn
Verdane is a specialist growth equity investment firm that partners with tech-enabled and sustainable European businesses to help them reach the next stage of international growth. Verdane can invest as a minority or majority investor, either in single companies or through portfolios of companies, and looks to deploy behind three core themes: the Digital Consumer, Software Everywhere and Sustainable Society. Verdane funds hold over €4 billion in total commitments and have made over 140 investments in fast-growing businesses since 2003. Verdane’s team of over 100 investment professionals and operating experts, based out of Berlin, Copenhagen, Helsinki, London, Oslo, and Stockholm, is dedicated to being the preferred growth partner to tech-enabled and sustainable businesses in Europe.
More info: www.verdane.com
Follow Verdane on LinkedIn
1 Assuming an average consumption of 2.5 and 5MWh per year
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Giovanni Rossi - firstname.lastname@example.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release
IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional
PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release
Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom